Literature DB >> 11332612

Alterations in the regulatory pathway involving p16, pRb and cdk4 in human chondrosarcoma.

J Asp1, S Inerot, J A Block, A Lindahl.   

Abstract

The G1 regulatory pathway involving p16, pRb and cdk4 in the cell cycle has been investigated in human chondrosarcoma. The protein expression of p16, pRb and cdk4 was analyzed by Western blot in cultured cells from eight chondrosarcomas and in two chondrosarcoma cell lines. Both cell lines and one other sample were negative for p16. Moreover, one of the cell lines was pRb-negative and showed a high expression of cdk4 as well. In the other cell line and in three other samples pRb of expected size were detected in addition to a shorter form of the protein. To further investigate the reasons for down-regulation of the p16 protein, the p16-coding gene CDKN2 was analyzed by polymerase chain reaction (PCR), methyl-specific PCR (MSP) and sequencing in all tumor samples as well as in corresponding tumor tissues from three of the samples. The p16-negative samples were all found to have homozygous deletion of CDKN2. Another sample showed partial gene methylation and a heterozygous position in codon 148 was detected in one sample. The same base substitution was also found in two of the tissue samples. Finally, cytogenetic analysis of the samples with homozygously deleted CDKN2 revealed multiple structural abnormalities in all three cases. In conclusion, the p16/pRb/cdk4 pathway may play an important role in the pathogenesis of some chondrosarcomas.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11332612     DOI: 10.1016/S0736-0266(00)00022-X

Source DB:  PubMed          Journal:  J Orthop Res        ISSN: 0736-0266            Impact factor:   3.494


  13 in total

Review 1.  Cartilage tumours and bone development: molecular pathology and possible therapeutic targets.

Authors:  Judith V M G Bovée; Pancras C W Hogendoorn; Jay S Wunder; Benjamin A Alman
Journal:  Nat Rev Cancer       Date:  2010-06-10       Impact factor: 60.716

2.  Molecular basis of differentiation therapy for soft tissue sarcomas.

Authors:  Gaurav Luther; Richard Rames; Eric R Wagner; Gaohui Zhu; Qing Luo; Yang Bi; Stephanie H Kim; Jian-Li Gao; Enyi Huang; Ke Yang; Linyuan Wang; Xing Liu; Mi Li; Ning Hu; Yuxi Su; Xiaoji Luo; Liang Chen; Jinyong Luo; Rex C Haydon; Hue H Luu; Lan Zhou; Tong-Chuan He
Journal:  Trends Cancer Res       Date:  2010

Review 3.  Genetic alterations in chondrosarcomas - keys to targeted therapies?

Authors:  Andre M Samuel; Jose Costa; Dieter M Lindskog
Journal:  Cell Oncol (Dordr)       Date:  2014-01-24       Impact factor: 6.730

4.  Loss of pRB and p107 disrupts cartilage development and promotes enchondroma formation.

Authors:  A S Landman; P S Danielian; J A Lees
Journal:  Oncogene       Date:  2012-11-12       Impact factor: 9.867

Review 5.  Molecular pathology of chondroid neoplasms: part 2, malignant lesions.

Authors:  W C Bell; M J Klein; M J Pitt; G P Siegal
Journal:  Skeletal Radiol       Date:  2006-10-18       Impact factor: 2.199

6.  Characterization of a new human cell line (CH-3573) derived from a grade II chondrosarcoma with matrix production.

Authors:  Silvia Calabuig-Fariñas; Rosario Gil Benso; Karoly Szuhai; Isidro Machado; José Antonio López-Guerrero; Danielle de Jong; Amando Peydró; Teresa San Miguel; Lara Navarro; Antonio Pellín; Antonio Llombart-Bosch
Journal:  Pathol Oncol Res       Date:  2012-02-15       Impact factor: 3.201

7.  Unique mutation portraits and frequent COL2A1 gene alteration in chondrosarcoma.

Authors:  Yasushi Totoki; Akihiko Yoshida; Fumie Hosoda; Hiromi Nakamura; Natsuko Hama; Koichi Ogura; Aki Yoshida; Tomohiro Fujiwara; Yasuhito Arai; Junya Toguchida; Hitoshi Tsuda; Satoru Miyano; Akira Kawai; Tatsuhiro Shibata
Journal:  Genome Res       Date:  2014-07-14       Impact factor: 9.043

8.  Global demethylation of rat chondrosarcoma cells after treatment with 5-aza-2'-deoxycytidine results in increased tumorigenicity.

Authors:  Christopher A Hamm; Hehuang Xie; Fabricio F Costa; Elio F Vanin; Elisabeth A Seftor; Simone T Sredni; Jared Bischof; Deli Wang; Maria F Bonaldo; Mary J C Hendrix; Marcelo B Soares
Journal:  PLoS One       Date:  2009-12-17       Impact factor: 3.240

Review 9.  Chondrosarcoma-from Molecular Pathology to Novel Therapies.

Authors:  Agnieszka E Zając; Sylwia Kopeć; Bartłomiej Szostakowski; Mateusz J Spałek; Michał Fiedorowicz; Elżbieta Bylina; Paulina Filipowicz; Anna Szumera-Ciećkiewicz; Andrzej Tysarowski; Anna M Czarnecka; Piotr Rutkowski
Journal:  Cancers (Basel)       Date:  2021-05-14       Impact factor: 6.639

10.  Central chondrosarcoma progression is associated with pRb pathway alterations: CDK4 down-regulation and p16 overexpression inhibit cell growth in vitro.

Authors:  Yvonne M Schrage; Suzanne Lam; Aart G Jochemsen; Anne-Marie Cleton-Jansen; Antonie H M Taminiau; Pancras C W Hogendoorn; Judith V M G Bovée
Journal:  J Cell Mol Med       Date:  2008-06-27       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.